Minimizing the potential for metabolic activation as an integral part of drug design

Evans, D.C.; Baillie, T.A.

Current Opinion in Drug Discovery and Development 8(1): 44-50

2005


ISSN/ISBN: 1367-6733
PMID: 15679171
Document Number: 589276
The formation of drug-protein adducts carries a risk of clinical toxicities that may not be predicted by preclinical safety studies. The process of minimizing the potential for metabolic activation at the lead optimization stage could therefore be viewed as a step for building quality into future generations of drug products.

Document emailed within 1 workday
Secure & encrypted payments